Accès ouvert déclaré 2018 article

Lasmiditan is an effective acute treatment for migraine

Bernice Kuca, Stephen David Silberstein, Linda A. Wietecha, Paul H. Berg, Gregory Dozier, Richard B. Lipton, Michael L. Adams, C. Alftine, Mohammed Basel Allaw, Lawrence E. Allen, Madhavi Ampajwala, Ladan Bakhtari, Kala R. Bhasker, David Bird, David Bolshoun, Judith A Brown, Paul Brownstone, Tami Bruce, Dina Burke, Rita Chuang, Rickie Conrady, Bethany Davis, Cedrice Davis, Mark A. Dawson, Donna DeSantis, Holly Dushkin, William Ellison, John E. Ervin, Beal Essink, Ibrahim Fakhouri, Thomas Fiel, William Fitzgibbons, David Francyk, Harry Geisberg, Jeff Geohas, Son Giep, Richard M. Glover, Narendra Godbole, William Grainger, Carl J. Griffin, Steven L. Halpern, Michael Y. Han, Louis Hiotis, Cynthia Huffman, Matthew A. Hummel, Donald Hurley, Anthony Inzerello, Ted Jagielo, Will Jennings, Scott A. Kaiser, Jennifer Kay, Ammar Khalifa, William Kirby, J. Larry Klein, Tracy Klein, James Kopp, Larry Kotek, Gary Korff, Mark A. Kutner, Robert Lending, Joseph R. Lentino, Thomas Lenzmeier, David Lesch, Peter Levins, Matthew Lewis, Adam Lowy, Charles A. Lunn, Kelli Maw, Brock McConnehey, Vishaal Mehra, Praful Mehta, J. Meli, Lubna Mirza, Clifford Molin, Robert Molpus, Linda Murray, Michael J. Noss, Mikhail Palatnik, Frank Rauzi, Naveed Razzaque, Michelle C. Reynolds, Robert A. Riesenberg, Ernie Riffer, Ana Maria Rodriguez, Daniel Schlosser, Douglas Schumacher, Randall Severance, Gerald Shockey, Richard Singer, William Smith, Jeffrey W. Stewart, Arkadiy Stolyar, Albert Tejada, Leslie M. Tharenos, John E. Titus, Mark S. Turner, Merle Turner, Aggy Vallanat, Sunil Verma, Sarah Vollbracht, Kerri L. Wilks, Hayes Williams, Wesley Williams, Thomas Wolf

272Citations signalées, ce qui n’est pas une note de qualité

5Institutions déclarées

1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Objective To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. Methods Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo and were asked to treat their next migraine attack within 4 hours of onset. Over 48 hours after dosing, patients used an electronic diary to record headache pain and the presence of nausea, phonophobia, and photophobia, one of which was designated their most bothersome symptom (MBS). Results Of the 1,856 patients who treated an attack, 77.9% had ≥1 cardiovascular risk factors in addition to migraine. Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [OR] 2.6, 95% confidence interval [CI] 2.0–3.6, p< 0.001), similar to those dosed with lasmiditan 100 mg (28.2%; OR 2.2, 95% CI 1.6–3.0, p< 0.001). Furthermore, compared with those dosed with placebo, more patients dosed with lasmiditan 200 mg (40.7% vs 29.5%; OR 1.6, 95% CI 1.3–2.1, p< 0.001) and lasmiditan 100 mg (40.9%; OR 1.7, 95% CI, 1.3–2.2, p< 0.001) were free of their MBS at 2 hours after dosing. Adverse events were mostly mild or moderate in intensity. Conclusions Lasmiditan dosed at 200 and 100 mg was efficacious and well tolerated in the treatment of acute migraine among patients with a high level of cardiovascular risk factors. ClinicalTrials.gov identifier NCT02439320. Classification of evidence This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Lasmiditan is an effective acute treatment for migraine
Date Crossref: 11/12/2018
Éditeur: Ovid Technologies (Wolters Kluwer Health)
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Montefiore Medical Center pays non établi dans la notice
Établissement de santé
Thomas Jefferson University MA pays non établi dans la notice
Université ou école supérieure
IQVIA (United States) pays non établi dans la notice
Entreprise
CoLucid Pharmaceuticals (United States) pays non établi dans la notice
Entreprise
Eli Lilly (United States) pays non établi dans la notice
Entreprise
Inc From CoLucid Pharmaceuticals (B.K.) pays non établi dans la notice
Entreprise
IQVIA (G.D.) pays non établi dans la notice
Institution
Montefiore Headache Center (R.B.L.) pays non établi dans la notice
Institution
Eli Lilly and Company (L.W. pays non établi dans la notice
Entreprise

Montefiore Medical Center, MA — Thomas Jefferson University et IQVIA (United States), avec 6 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Migraine and Headache StudiesNeurological Complications and SyndromesNeurological Disorders and Treatments

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI